News Agency
Men's Weekly

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

  • Written by PR Newswire
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

Trial results anticipated in early Q3 this year

SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept,...

Read more: Enrolment completed in Actinogen's XanaCIDD phase 2a cognition depression trial

How Signage Shapes Business Visibility And Customer Perception

In today’s competitive commercial environment, signage is far more than just a display element—it acts as a silent communicator between a business and its audience. Whether positioned outdoors or within a retail or corporate space, it provides immediate information about what... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion